Rapid communication Open Access
Like 0


During predominant circulation of SARS-CoV-2 Omicron XBB.1.5 and other XBB sublineages (April–June 2023), we found that a second or third booster of Comirnaty bivalent Original/Omicron BA.4-5 mRNA vaccine, versus a first booster received at least 120 days earlier, was effective in preventing severe COVID-19 for more than 6 months post-administration in persons 60 years and above. In view of autumn 2023 vaccination campaigns, use of bivalent Original/Omicron BA.4-5 mRNA vaccines might be warranted until monovalent COVID-19 vaccines targeting Omicron XBB.1 sublineages become available.


Article metrics loading...

Loading full text...

Full text loading...



  1. World Health Organization (WHO). Statement on the antigens composition of COVID-19 vaccines. Geneva: WHO; 2023. Available from: https://www.who.int/news/item/18-05-2023-statement-on-the-antigen-composition-of-covid-19-vaccines
  2. European Centre for Disease Prevention and Control (ECDC), European Medicines Agency (EMA). ECDC-EMA statement on updating COVID-19 vaccines composition for new SARS-CoV-2 virus variants.Stockholm and Amsterdam: ECDC and EMA. [Accessed: 17 Jul 2023]. Available from: https://www.ema.europa.eu/en/documents/other/ecdc-ema-statement-updating-covid-19-vaccines-composition-new-sars-cov-2-virus-variants_en.pdf
  3. World Health Organization (WHO). Weekly Epidemiological Update on COVID-19 – 6 July 2023. Geneva: WHO. [Accessed: 17 Jul 2023]. Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---6-july-2023
  4. Link-Gelles R, Ciesla AA, Roper LE, Scobie HM, Ali AR, Miller JD, et al. Early estimates of bivalent mRNA booster dose vaccine effectiveness in preventing symptomatic SARS-CoV-2 infection attributable to Omicron BA.5- and XBB/XBB.1.5-related sublineages among immunocompetent adults - increasing community access to testing program, United States, December 2022-January 2023. MMWR Morb Mortal Wkly Rep. 2023;72(5):119-24.  https://doi.org/10.15585/mmwr.mm7205e1  PMID: 36730051 
  5. Lin DY, Xu Y, Gu Y, Zeng D, Sunny SK, Moore Z. Durability of bivalent boosters against Omicron subvariants. N Engl J Med. 2023;388(19):1818-20.  https://doi.org/10.1056/NEJMc2302462  PMID: 37043647 
  6. Wee LE, Pang D, Chiew C, Tan J, Lee V, Ong B, et al. Long-term real-world protection afforded by third mRNA doses against symptomatic SARS-COV-2 infections, COVID-19-related emergency attendances and hospitalizations amongst older Singaporeans during an Omicron XBB wave. Clin Infect Dis. 2023;ciad345.  https://doi.org/10.1093/cid/ciad345  PMID: 37280047 
  7. Shrestha NK, Burke PC, Nowacki AS, Simon JF, Hagen A, Gordon SM. Effectiveness of the Coronavirus Disease 2019 Bivalent Vaccine. Open Forum Infect Dis. 2023;10(6):ofad209.  https://doi.org/10.1093/ofid/ofad209  PMID: 37274183 
  8. European Centre for Disease Prevention and Control (ECDC). Interim public health considerations for COVID-19 vaccination roll-out during 2023. Stockholm: ECDC; 2023. Available from: https://www.ecdc.europa.eu/en/publications-data/interim-public-health-considerations-covid-19-vaccination-roll-out-during-2023
  9. GitHub. COVID-19 Opendata Vaccini. [Accessed: 17 Jul 2023]. Available from: https://github.com/italia/covid19-opendata-vaccini
  10. European Medicines Agency (EMA). Adapted vaccine targeting BA.4 and BA.5 Omicron variants and original SARS-CoV-2 recommended for approval. Amsterdam: EMA; 2022. Available from: https://www.aifa.gov.it/documents/20142/1621464/2022.09.13_com-EMA_raccomandazione_vaccino_adattato_Comirnaty_B4-5_EN.pdf
  11. Italian Medicines Agency (AIFA). AIFA authorises Comirnaty Original bivalent vaccine for Sars-Cov-2 Omicron BA.4-5 variants. Rome: AIFA; 2022. Available from: https://www.aifa.gov.it/documents/20142/1621225/Comunicato_AIFA_n.697_EN.pdf
  12. Italian Government, Presidency of the Council of Ministers. Report Vaccini anti COVID19. [COVID19 Vaccines Report]. Rome: Italian Government; 2020. Italian. Available from: https://www.governo.it/it/dipartimenti/commissario-straordinario-lemergenza-covid-19/15974
  13. Italian National Institute of Health (ISS), EpiCentro. Epidemiology for public health - COVID-19 integrated surveillance: key national data. Rome: ISS. [Accessed: 17 Jul 2023]. Available from: https://www.epicentro.iss.it/en/coronavirus/sars-cov-2-integrated-surveillance-data
  14. European Centre for Disease Prevention and Control (ECDC). Data on SARS-CoV-2 variants in the EU/EAA. Stockholm: ECDC. [Accessed: 17 Jul 2023]. Available from: https://www.ecdc.europa.eu/en/publications-data/data-virus-variants-covid-19-eueea
  15. Italian National Institute of Health (ISS), EpiCentro. Sorveglianza genomica del virus SARS-CoV-2 e delle sue varianti di interesse in sanità pubblica in Italia. [Genomic surveillance of the SARS-CoV-2 virus and its variants of interest in public health in Italy]. Rome: ISS. [Accessed: 17 Jul 2023]. Italian. Available from: https://www.epicentro.iss.it/coronavirus/sars-cov-2-monitoraggio-varianti
  16. European Centre for Disease Prevention and Control (ECDC). Case definition for coronavirus disease 2019 (COVID-19), as of 3 December 2020. Stockholm: ECDC. [Accessed: 17 Jul 2023]. Available from: https://www.ecdc.europa.eu/en/covid-19/surveillance/case-definition
  17. World Health Organization (WHO). International guidelines for certification and classification (coding) of COVID-19 as cause of death. Geneva: WHO; 2020. Available from: https://www.who.int/publications/m/item/international-guidelines-for-certification-and-classification-(coding)-of-covid-19-as-cause-of-death
  18. Mateo-Urdiales A, Sacco C, Fotakis EA, Del Manso M, Bella A, Riccardo F, et al. Relative effectiveness of monovalent and bivalent mRNA boosters in preventing severe COVID-19 due to omicron BA.5 infection up to 4 months post-administration in people aged 60 years or older in Italy: a retrospective matched cohort study. Lancet Infect Dis. 2023;S1473-3099(23)00374-2. (Forthcoming).  https://doi.org/10.1016/S1473-3099(23)00374-2  PMID: 37478877 
  19. Madhi SA, Feikin DR. Are bivalent vaccines better than ancestral-virus monovalent vaccines in protecting against severe omicron COVID-19? Lancet Infect Dis. 2023;S1473-3099(23)00425-5. (Forthcoming).  https://doi.org/10.1016/S1473-3099(23)00425-5  PMID: 37478878 
  20. Marziano V, Guzzetta G, Menegale F, Sacco C, Petrone D, Mateo-Urdiales A, et al. Estimating SARS-CoV-2 infections and associated changes in COVID-19 severity and fatality. Influenza Other Respir Viruses. 2023. (Forthcoming).
  21. Italian Medicines Agency (AIFA). Modifica della determina n. DG/153/2022 dell'11 aprile 2022 di inserimento dell'indicazione «seconda dose booster» dei medicinali «Comirnaty» e «Spikevax» nell'elenco dei medicinali ai sensi della legge 23 dicembre 1996, n. 648. (Determina n. DG/301/2022). (22A04093) (GU Serie Generale n.161 del 12-07-2022). [Italian Medicines Agency. Resolution of 12 July 2022. Amendment of Resolution no. DG/153/2022 of 11 April 2022 inserting the indication “second dose booster” of the medicines “Comirnaty” and “Spikevax” in the list of medicines pursuant to Law no. 648 of 23 December 1996.] Rome: AIFA; 2022. Italian. Available from: https://www.gazzettaufficiale.it/atto/serie_generale/caricaDettaglioAtto/originario?atto.dataPubblicazioneGazzetta=2022-07-12&atto.codiceRedazionale=22A04093&elenco30giorni=false

Data & Media loading...

Supplementary data

Submit comment
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error